ASTRAZENECA PLC (AZN)
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
What ASTRAZENECA PLC does
AstraZeneca PLC is a multinational biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, and other therapeutic areas. The company operates a global portfolio of innovative medicines and is actively pursuing strategic acquisitions and licensing agreements to expand its treatment capabilities. Recent activities include licensing novel EGFR inhibitors for lung cancer and advancing clinical trials in amyloid cardiomyopathy treatment.
Themes: Oncology / EGFR-targeted lung cancer
Fundamentals
- Price$164.52 as of 2026-07-20 close
- Market cap$195.3B as of 2026-07-21
- 1-year return+23.1% as of 2026-07-20 close
- P/E25.32 as of 2026-07-21
- Net margin+17.2% as of 2026-07-21
- Gross margin+81.4% as of 2026-07-21
- ROE+22.3% as of 2026-07-21
- Debt / equity0.72 as of 2026-07-21
- Revenue growth (YoY)+9.9% as of 2026-07-21
- Beta1.39 as of 2026-07-21
Dividend: yield +1.9%; pays a dividend.
Key risks (from latest filing)
["Clinical trial failures – CARDIO-TTRansform trial did not meet its primary efficacy endpoint, indicating drug development uncertainty and potential loss of expected revenue streams."]
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($2M) — 1 selling insider
- Last 180 days0 buys · 1 sell ($2M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-05-20. As of 2026-07-21.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AZN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
AZN shows up in…
Frequently asked questions
What does ASTRAZENECA PLC (AZN) do?
AstraZeneca PLC is a multinational biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, and other therapeutic areas. The company operates a global portfolio of innovative medicines and is actively pursuing strategic acquisitions and licensing agreements to expand its treatment capabilities.
Does AZN pay a dividend?
Yes — ASTRAZENECA PLC (AZN) pays a dividend, with an indicated yield of about 1.95% (Finnhub, as of 2026-07-21). Informational only — not financial advice.
Who are ASTRAZENECA PLC's (AZN) competitors?
Notable peers of ASTRAZENECA PLC (AZN) include Merck. This peer set is informational only — not financial advice.
Where does stocks-llm's data on AZN come from?
Fundamentals and prices come from Finnhub, as of 2026-07-21; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: Finnhub, as of 2026-07-21. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.